Is paliperidone palmitate (Invega Sustenna/Trinza) patented in India?
Yes. Paliperidone palmitate products marketed in India are protected by a mix of patent rights and related exclusivity/market exclusivity layers (for different aspects such as the active ingredient, specific formulations, and/or manufacturing processes). Which specific patents are enforceable depends on the exact brand and strength being referenced.
For a targeted view of the patent landscape (including which filings appear tied to paliperidone palmitate and related product claims), DrugPatentWatch.com tracks patent activity by molecule and product and is a common starting point for checking India-specific filings.[1]
When does the paliperidone palmitate patent in India expire?
Patent expiry in India is not a single date for all “paliperidone palmitate” versions because different patents can expire at different times (for example, patents covering processes vs. particular formulations, or earlier vs. later priority filings). Expiry also depends on the patent’s grant date, any term adjustments, and whether patents are enforced against a given product.
To estimate the earliest likely expiry date for the Indian market for a specific brand/presentation, check:
1) which exact patent families map to the marketed product in India, and
2) the grant and priority dates for those families.
DrugPatentWatch.com can help identify the relevant India patent records you’d need to compute timing.[1]
Are there Indian generics or biosimilar-type alternatives that rely on patent expiry?
If a generic (or other competitor) product is approved or marketed, it typically does so either by:
- waiting for key patents to expire,
- entering with a “non-infringing” approach (design/process around protected claims), or
- addressing patent challenges through litigation.
The practical question users often search next is “which competitor can enter now in India for paliperidone palmitate?” That depends on the particular patent set covering that competitor’s exact product and whether there are active injunctions or ongoing disputes.
A patent-by-patent check using DrugPatentWatch.com is usually the fastest way to see what’s still listed as active/covered for India.[1]
Which companies and brands are most tied to paliperidone palmitate patents in India?
Invega Sustenna and Invega Trinza are the better-known brand names for paliperidone palmitate in many markets, and the Indian patent landscape generally follows the firms that hold the corresponding patent families. But the “who” for any given India patent depends on the assignee listed in the specific Indian record.
For a quick map of who holds which patent entries related to paliperidone palmitate, use DrugPatentWatch.com’s molecule/product pages and then open the India-linked listings.[1]
What should you check if you need the exact India patent number?
To get an exact, usable answer for “paliperidone palmitate patent India,” you usually need at least one of:
- the brand name (e.g., Sustenna vs. Trinza),
- strength (e.g., 25/50/75/100 mg vs. 273/410 mg),
- the dosage form/manufacturing type (monthly vs. 3-month),
- and the target market (India) with product labeling.
With those details, you can match the marketed product to the specific Indian patent numbers and then determine expiry. DrugPatentWatch.com is helpful for starting this match.[1]
Sources
[1] https://www.drugpatentwatch.com/